April 20, 2021Thrombosis and Haemostasis
Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study
Why the study?
Recurrent VTE despite curative anticoagulation is frequent in cancer patients, so this prospective study aimed to validate the Ottawa risk score to identify those at high risk.
Does the Ottawa score accurately predict recurrent VTE in cancer patients receiving tinzaparin?
Population
409 adult cancer patients with recent symptomatic or incidental lower limb DVT or PE
Comparison
Ottawa score high risk (≥ 1) vs low risk
Design
Prospective multicenter observational cohort study
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Ottawa score failure to stratify recurrence cautions against routine use in cancer VTE; challenges prior validations and leaves open need for better tools.
Structured PICO
Does the Ottawa score accurately predict recurrent VTE in cancer patients receiving tinzaparin?
P
Population
409 adult cancer patients with a recent diagnosis of symptomatic or incidental lower limb deep vein thrombosis or pulmonary embolism (PE), median age 68 years. Main primary cancer sites: lung (31.3%), lower digestive tract (14.4%), and breast (13.9%).
I
Intervention
Ottawa risk score assessment (all patients treated with tinzaparin for 6 months)
C
Comparator
Ottawa low risk versus high risk (score ≥ 1) groups
O
Outcome
Recurrence of symptomatic or asymptomatic VTE within the first 6 months of treatmenthard clinical
The Ottawa score failed to accurately predict recurrent VTE in cancer patients receiving tinzaparin, demonstrating poor discriminative ability with a C-statistic of 0.60.
Cite This Study
Girard et al. (2021) studied this question.